Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Vir Biotechnology Inc
(NQ:
VIR
)
10.66
+0.56 (+5.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vir Biotechnology Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
What 5 Analyst Ratings Have To Say About Vir Biotechnology
November 04, 2022
Over the past 3 months, 5 analysts have published their opinion on Vir Biotechnology (NASDAQ:VIR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
November 04, 2022
Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates.
Via
Investor's Business Daily
Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday
November 04, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotech Secures US Government Contract For Influenza & Other Infectious Disease Candidates
October 04, 2022
Via
Benzinga
This Hepatitis Stock Has 'Multiple Paths To Value Creation,' Expects To Double, Bullish Analyst Predicts
September 14, 2022
Via
Benzinga
Earnings Scheduled For November 3, 2022
November 03, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Via
Benzinga
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
October 31, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
October 28, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
October 20, 2022
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to...
Via
Benzinga
Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment
August 10, 2022
Via
Benzinga
This Addiction Drug Shows Some Potential Against Long COVID Symptoms
October 19, 2022
Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection.
Via
Benzinga
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
October 18, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
October 11, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It
October 04, 2022
BARDA will pay Vir up to $1 billion to develop its experimental treatment.
Via
Investor's Business Daily
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
October 04, 2022
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
3 Biotech Stocks to Buy Now for Extraordinary Gains
September 20, 2022
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.
Via
InvestorPlace
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
September 16, 2022
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies.
Via
Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
September 02, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low...
Via
Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
August 15, 2022
The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
11 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 10, 2022
Gainers
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Vir Biotechnology Earnings Preview
August 08, 2022
Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that Vir...
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For August 9, 2022
August 09, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Via
Benzinga
Earnings Preview: Vir Biotechnology
August 03, 2022
Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Vir...
Via
Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
July 25, 2022
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.
Via
InvestorPlace
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.